Abstract
The paper by Robertson et al. intends to provide “a unified, broad and fresh review of methodological and practical issues to consider” as a contribution to the ongoing debate concerning RAR in clinical trials. Simulations carried out by different authors seem to disprove its usefulness both for statistical inference and as a safeguard for the care of patients in the trial. I argue that the arguments brought forward so far are inconclusive, since the inferential considerations are sometimes incomplete or incorrect, and some simulation studies unconvincing. A Bayesian stand is very common, but often not fully understood.
Citation
Alessandra Giovagnoli. "Comment: Is Response-Adaptive Randomization a “Good Thing” or Not in Clinical Trials? Why We Cannot Take Sides." Statist. Sci. 38 (2) 224 - 228, May 2023. https://doi.org/10.1214/23-STS865E
Information